drugset
drugset / Trial / NCT00673504

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

NCT00673504 ↗

Phase 2 Completed 105 enrolled Central European Society for Anticancer Drug Research
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objective: to evaluate whether the addition of sunitinib prolongates the Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving first-line gemcitabine chemotherapy.

Timeline

Start
2008-04
Primary completion
2011-10
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Sunitinib Small molecule 50 mg —

Indications

malignant pancreatic neoplasm